Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers.

ABSTRACT:

Background

Carboplatin remains integral for treatment of gynaecological malignancies and dosing is based on glomerular filtration rate (GFR). Measurement via radiotracer decay [nuclear medicine GFR (nmGFR)] is ideal. However, this may be unavailable. Therefore GFR is often estimated using formulae that have not been validated in patients with cancer and/or specifically for gynaecological malignancies, leading to debate over optimal estimation. Suboptimal GFR estimation may affect efficacy or toxicity.

Methods

We surveyed several UK National Health Service Trusts to assess carboplatin dosing practise. We then explored single-centre accuracy, bias and precision of various formulae for GFR estimation, relative to nmGFR, before validating our findings in an external cohort.

R

SUBMITTER: Samani A 

PROVIDER: S-EPMC9058909 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature